Two injections, two completely different jobs

If you have been offered a knee injection and are trying to understand which one makes sense for your situation, the first thing to know is that ChondroFiller® and hyaluronic acid (HA) are not competing versions of the same treatment. They do entirely different jobs — and they are aimed at different problems inside the knee.

ChondroFiller® is an injectable collagen scaffold. Placed under ultrasound guidance directly into a focal cartilage defect, it gels in situ and provides a structural matrix that recruits the body's own cells to initiate repair from within the cavity outward. Think of it as patching a pothole: the defect needs to be discrete, bordered, and physically containable.

HA viscosupplementation works more like re-oiling a bearing. Injected into the joint space, it restores the lubricating and cushioning properties of synovial fluid across the joint surface as a whole. It does not fill or scaffold a structural lesion.

The practical consequence is that choosing between them starts with MRI-confirmed lesion morphology, not symptom severity alone. A focal, well-bordered cartilage defect and a diffusely worn, symptomatic joint are different clinical problems that call for different solutions.

How ChondroFiller works — and what it needs to succeed

The collagen gel that forms inside the defect does two things simultaneously: it fills the physical void left by cartilage loss, and it acts as a chemotactic scaffold — signalling to progenitor cells in the surrounding synovium and underlying subchondral bone to migrate inward. This process, known as acellular matrix-induced chondrogenesis, means the injection itself contains no cells. The repair depends on the patient's own biology responding to the scaffold over the weeks and months that follow.

What makes this work — or not — is the geometry of the defect. The surrounding cartilage borders must be reasonably intact, because without those walls the collagen gel cannot remain contained. An isolated, well-bordered ICRS Grade III or IV lesion on MRI provides the cavity the scaffold needs to sit in, integrate with adjacent tissue, and mature progressively. Where cartilage loss is widespread and there is no discrete containable cavity, there is no physical structure for the gel to fill — which is why imaging-based patient selection matters before any clinical decision is made.

At Lincolnshire Knee, the delivery is an outpatient procedure: ChondroFiller is placed under real-time ultrasound guidance, with the needle positioned within the defect under direct imaging and the scaffold injected as a liquid that gels in situ. There is no theatre admission, no general anaesthetic, and no incision. The biological repair mechanism is the same regardless of delivery route; it is the anatomy of the lesion, confirmed on MRI, that determines whether the approach is appropriate for a given patient.

How hyaluronic acid works — and who benefits most

Viscosupplementation works by supplementing the joint fluid itself. In a healthy knee, synovial fluid contains high-molecular-weight hyaluronic acid — averaging around 7 MDa per molecule — which gives it the viscoelastic properties needed to cushion the joint under load and reduce friction between articular surfaces. In osteoarthritic knees, synovial HA degrades and thins, contributing to the pain and stiffness patients experience day to day.

An HA injection replenishes that environment. Delivered into the joint space, it restores the lubricating and cushioning properties of synovial fluid across the joint as a whole. The benefit is symptomatic and functional — not structural. No cartilage volume is replaced or restored.

The strongest evidence sits with mild-to-moderate knee OA (Kellgren-Lawrence Grade I–III). Bellamy et al.'s 2006 Cochrane review (CD005321) established HA's symptomatic benefit over placebo; Bannuru et al.'s 2015 network meta-analysis in the Annals of Internal Medicine confirmed effectiveness for this population. In end-stage (Grade IV) disease, benefit narrows considerably, and most HA trials systematically exclude these patients — a gap documented by Nicholls et al. (2019).

Molecular weight matters clinically. Higher-MW formulations tend to sustain lubrication for longer, and Concoff et al.'s 2017 systematic review found that multi-injection regimens (3–5 courses) and single high-purity products produce broadly comparable outcomes, which offers flexibility in how treatment is structured around a patient's routine.

Guideline opinion is genuinely divided. OARSI offers conditional support for HA viscosupplementation; AAOS and ACR remain more cautious, citing heterogeneity in trial data. That disagreement reflects variability in HA products and patient populations rather than a verdict against the therapy — HA remains a clinically legitimate option for appropriately selected patients.

What the evidence shows for each

The available outcome data points in different directions depending on what is being measured and in whom.

For ChondroFiller, the best available evidence comes from the Jerosch et al. prospective post-market clinical follow-up (PMCF) study and associated European cohorts. Knee IKDC scores improved by approximately 30 points at 12 months — all exceeding the minimum clinically important difference (MCID) of 16.7 points — with the gain sustained at three years: a mean improvement of 32.4 points and an average functional score of 80. MRI MOCART scores (which run from 0 to 100) rose from 65.3 at four weeks to 81.6 at one year, confirming progressive scaffold maturation; one-year scores of 81.6–84.3 across European studies indicate more than 80% defect-cavity filling and sound integration with surrounding native cartilage.

These studies are manufacturer-sponsored PMCF data and single-arm cohorts. Independent comparative RCT data against HA or other scaffold systems does not currently exist — a meaningful limitation for evidential confidence, though one that does not negate what the outcome figures show within their own populations.

The HA evidence base is broader and more independently sourced. Bellamy et al.'s 2006 Cochrane review (CD005321) and Bannuru et al.'s 2015 network meta-analysis in the Annals of Internal Medicine confirm clinically meaningful pain and function gains for mild-to-moderate knee OA, across multiple products and injection protocols; acknowledged heterogeneity in formulation and regimen is the main caveat.

No head-to-head trial directly comparing ChondroFiller with HA in matched knee populations has been conducted. That absence is not a gap to fill with speculation — it reflects the fact that these injections address structurally different presentations. The decision belongs to imaging findings, not to a comparative outcome score that does not yet exist.

How to decide which injection suits your knee

Imaging, not symptom severity, is where the decision begins — and specifically, whether an MRI shows a focal, well-bordered cartilage cavity that can physically contain and retain a collagen gel.

If a contained Grade III or IV defect is confirmed on MRI, with healthy surrounding cartilage forming intact borders on all sides, ChondroFiller becomes the appropriate candidate to consider. The gel cannot fill what it cannot be held within; border integrity is the structural prerequisite, not an additional preference.

Where cartilage loss is diffuse — thinning spread across a compartment without a discrete defect cavity — HA viscosupplementation addresses the symptomatic joint environment directly. It does not require a bounded lesion because it acts across the joint surface as a whole, restoring lubrication rather than occupying a structural void.

The bone-on-bone framing deserves care here. ChondroFiller carries no strict age ceiling, and the phrase 'bone-on-bone' alone does not determine candidacy. A patient with broader compartment wear may still have a focal, containable lesion identifiable on MRI; if so, the scaffold's prerequisites are met. What rules ChondroFiller out is the absence of a containable defect — not severity language used in clinic shorthand.

Where OA is genuinely end-stage across a broad compartment, with no focal lesion to address and HA unlikely to produce meaningful benefit, neither injection is the appropriate primary option. Osteotomy or arthroplasty are the relevant pathways to discuss at that stage.

For patients with mixed presentations — a focal defect sitting within a more broadly osteoarthritic knee — the decision becomes more nuanced and is best resolved through a consultant-led assessment using detailed MRI, ideally with cartilage-specific sequencing. No standardised protocol for combination or staged injection in this setting has been established in the published literature.

Getting the right assessment in Lincolnshire

Choosing between these two injections ultimately depends on what the MRI actually shows — not on symptom severity alone, and not on a blanket OA diagnosis. The clinical question is specific: is there a focal, well-bordered cartilage defect present, or is the loss diffuse? Answering that with confidence requires cartilage-specific imaging rather than a standard diagnostic scan.

Lincolnshire Knee uses onMRI™ AI-driven analysis to provide detailed cartilage and meniscus segmentation, T2 mapping, and defect characterisation — the kind of lesion-level detail that directly informs whether a scaffold pathway or viscosupplementation is the more appropriate route. Where loading patterns and biomechanical contributors to cartilage stress are relevant, MAI Motion® objective gait assessment adds functional context to the imaging picture.

Consultations are available at Sleaford NG34 and Grantham NG31 without a GP referral and without NHS-style waiting lists. To clarify which injection pathway, if any, fits your knee's specific findings, book an assessment at lincolnshireknee.co.uk.